Influenza: Page 4

Longhorn touts study of collection device for COVID/flu testing

By LabPulse.com staff writers

The research article is titled "Rapid and Safe Detection of SARS-CoV-2 and Influenza Virus RNA Using Onsite qPCR Diagnostic Testing from Clinical Specimens Collected in Molecular Transport Medium."

July 8, 2021

Market for biomarker-based infectious disease tests to hit $15B

By Bruce Carlson

Biomarkers include more than 1,000 substances that serve as reagents, consumables, and/or test components for a number of medical-related diagnostic and research applications. Substances that detect and measure genetic changes in patient samples are also included in the sales statistics.

May 25, 2021

Boom in COVID testing drives Quidel's Q1 financials

By LabPulse.com staff writers

The company expects revenues in the first quarter of 2021 to be in the range of $374 million to $376 million, up approximately 114% from $174.7 million in the prior year's first quarter.

April 22, 2021

Qiagen secures EUA for COVID-19 test

By LabPulse.com staff writers

NeuMoDx Flu A-B/ respiratory syncytial virus (RSV)/SARS-CoV-2 Vantage is a polymerase chain reaction (PCR) assay that will enable clinicians to identify the cause of respiratory viral infection, whether it's due to SARS-CoV-2, influenza, or RSV.

March 28, 2021

Thermo Fisher completes Mesa Biotech acquisition

By LabPulse.com staff writers

Mesa Biotech is known for its Accula system, a point-of-care polymerase chain reaction (PCR)-based testing platform for infectious disease diagnosis. Besides COVID-19, Accula also tests for influenza, respiratory syncytial virus (RSV), and group A Streptococcus.

February 25, 2021

Bio-Rad's sales rise in Q4, full fiscal year

By LabPulse.com staff writers

For the fourth quarter, Bio-Rad posted net sales of $789 million, an increase of 26.5% compared with sales of $624 million in the same period the year before. The company's net income for the most recent period was $839 million, compared with income of $554 million in the fourth quarter of fiscal 2019.

February 11, 2021

FDA grants EUA for BD's COVID-19, flu assay

By LabPulse.com staff writers

The EUA has updated information that addresses variants of the SARS-COV-2 virus, including variants from the U.K. and South Africa. However, the ability to detect new variants also applies to the standalone SARS-CoV-2 test for the BD Max system.

February 11, 2021

CAP comments on Biden's COVID-19 plans

By LabPulse.com staff writers

Major problems exist in the diagnostic testing process, whether it's obtaining testing supplies, continued access to services, or the financial effect on laboratories. CAP encourages the federal government to improve transparency, coordination, and management of testing supplies along with covering multiplex polymerase chain reaction (PCR) respiratory viral panel (RVP) tests.

January 28, 2021

COVID-19 testing boosts molecular point-of-care market

By Bruce Carlson

Molecular POC diagnostic solutions offer improvements in the sensitivity and specificity of existing near-patient and rapid tests while expanding the diagnostic capabilities at points of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts in the developing world, and are used to assess conditions or admit patients. The concept of mPOC is to combine the accessibility of POC testing with the accuracy of molecular technology. Disclosure: LabPulse.com is a sister company of Kalorama Information.

January 26, 2021

GeneIQ debuts a SARS-CoV-2, RSV, influenza A/B test

By LabPulse.com staff writers

The four-in-one test is available for symptomatic individuals. Patients are tested using nasal swabs, and the result turnaround time is about 24 hours.

January 5, 2021

Quidel nabs EUA from FDA for SARS-CoV-2 antigen test

By LabPulse.com staff writers

The QuickVue SARS Antigen test leverages Quidel's QuickVue platform for influenza A and B testing and is designed for use in the first five days of symptom onset in people with suspected cases of COVID-19.

December 20, 2020

COVID-19 challenges the landscape of rapid testing for infectious diseases

By Joseph Constance

The COVID-19 pandemic has changed the rapid testing landscape, according to Nikolina Babic, PhD, of the department of pathology and laboratory medicine at the Medical University of South Carolina in Charleston.

December 16, 2020

Previous Page

Page 4 of 7

Next Page